Published in final edited form as:

Neurobiol Aging. 2010 June ; 31(6): 917–925. doi:10.1016/j.neurobiolaging.2008.07.003.

Evidence that γ -Secretase Mediates Oxidative Stress-Induced β -Secretase Expression in Alzheimer's Disease

Dong-Gyu Jo^{1,2}, Thiruma V. Arumugam¹, Ha-Na Woo², Jong-Sung Park², Sung-Chun Tang^{1,3}, Mohamed Mughal¹, Dong-Hoon Hyun^{1,4}, Jun-Hyung Park², Yun-Hyung Choi², A-Ryeong Gwon², Simonetta Camandola¹, Aiwu Cheng¹, Huaibin Cai⁵, Weihong Song⁶, William R. Markesbery⁷, and Mark P. Mattson^{1,8}

¹Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, Baltimore, MD.

²College of Pharmacy, Sungkyunkwan University, Suwon, Korea.

³Stroke Center, Department of Neurology, National Taiwan University Hospital, Taiwan.

⁴Division of Molecular Life Science, Ewha Women's University, Seoul, Korea.

⁵Department of Psychiatry, Brain Research Center, and Graduate Program in Neuroscience, University of British Columbia, BC, Canada.

⁶Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD.

⁷Sanders-Brown Research Center on Aging, University of Kentucky, Lexington, KY.

⁸Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD.

Abstract

β -secretase (BACE1), an enzyme responsible for the production of amyloid β -peptide (A β), is increased by oxidative stress and is elevated in the brains of patients with sporadic Alzheimer's disease (AD). Here we show that oxidative stress fails to induce BACE1 expression in presenilin-1 (γ -secretase)-deficient cells and in normal cells treated with γ -secretase inhibitors. Oxidative stress-induced β -secretase activity and sAPP β levels were suppressed by γ -secretase inhibitors. Levels of γ - and β -secretase activities were greater in brain tissue samples from AD patients compared to non-demented control subjects, and the elevated BACE1 level in the brains of 3xTgAD mice was reduced by treatment with a γ -secretase inhibitor. Our findings suggest that γ -secretase mediates oxidative stress-induced expression of BACE1 resulting in excessive A β production in AD.

Keywords

β -secretase; Alzheimer's disease; oxidative stress; γ -secretase

Correspondence: Mark P. Mattson (mattsonm@grc.nia.nih.gov) Phone 410 558–8463 FAX 410 558–8465.

Disclosure Statement

The authors declare that they have no actual or potential conflicts of interest to disclose. Appropriate approval and procedures were used concerning human subjects and animals.

1. Introduction

Sequential proteolytic cleavages of the β -amyloid precursor protein (APP) by β -secretase (BACE1) and γ -secretase generate the amyloid β -peptide (A β) believed responsible for damage and death of neurons that occurs in Alzheimer's disease (AD) [16]. The causes of A β accumulation in sporadic AD remain unclear, but may include age-related increases in oxidative stress [16].

The amount of lipid peroxidation is increased in AD patients and is correlated with the clinical severity of the disease [24]. In the Tg2576 mice, increased lipid peroxidation is localized in brain regions involved with A β plaques and precedes the onset of A β plaque deposition [25]. Moreover, several risk factors for AD are known to increase cellular oxidative stress in the brain including aging and ApoE4 genotype [3,18]. These observations suggest that oxidative stress is integral to AD pathogenesis, although it remains unclear whether oxidative stress is a cause or consequence of AD neuropathology.

It has been reported that BACE1 expression and activity are elevated in the postmortem brain regions affected by AD [10,14] and in mouse models of AD [31], suggesting a role for BACE1 in AD. BACE1 expression is also increased in conditions known to involve oxidative stress including ischemia [31], hypoxia [27] and in cultured neuronal cells exposed to hydrogen peroxide or the lipid peroxidation product 4-hydroxy-2,3 nonenal (HNE) [28,29]. In addition, we recently found that ischemia and hypoxia increase γ -secretase activity [1]. In the present study, we provide evidence for previously unknown links between oxidative stress γ -secretase activity and BACE1 expression in the pathogenesis of AD.

2. Materials and methods

2.1. Human subjects and brain specimens

Inferior parietal lobule and cerebellum specimens from the brains of 10 patients with AD and 10 control subjects that had been enrolled in the University of Kentucky Alzheimer's Disease Center Autopsy Program were used for this study. All patients with AD met both clinical diagnostic criteria and neuropathological diagnostic criteria of AD [20]. The control subjects had no history or neuropathological signs of a brain disorder. At autopsy, tissue specimens were rapidly removed and frozen, and were stored at -80°C .

2.2. Animals and treatment with γ -secretase inhibitor

Seven month-old PS1 mutant knock-in mice (PS1KI) (8), triple-transgenic AD mice (3xTgAD; swAPP, PS1-M146V, tau-P301L) (21), and wild type mice of the same genetic backgrounds were maintained in our animal facility under pathogen-free conditions on a 12 hr light/12 hr dark cycle with continuous access to food and water. Mice were treated with the γ -secretase inhibitor DAPT (100 mg/kg, subcutaneously), or vehicle every day for 7 days and the mice were then euthanized and brains removed for processing. All procedures were approved by the NIA Animal Care and Use Committee.

2.3. Cell culture and experimental treatments

Human neuroblastoma SH-SY5Y cells and immortalized mouse embryonic fibroblasts (MEF) from wild-type, PS1 $^{-/-}$, PS2 $^{-/-}$, PS1 $^{-/-}$ /PS2 $^{-/-}$ mice (generous gifts from B. De Strooper, Leuven, Belgium) and BACE1 $^{-/-}$ mice were cultured in Dulbecco's minimum Eagle's medium (DMEM) (GIBCO, Carlsbad, CA) supplemented 10% with fetal bovine serum (FBS) (GIBCO) and 1% penicillin/streptomycin (GIBCO). Primary dissociated cell cultures of hippocampal and cortical neurons were prepared from 18-day-old rat embryos by using methods described previously [17]. Experiments were performed in cells that had been

in culture for 6–8 days. The atmosphere consisted of 6% CO₂/94% room air and was maintained near saturation with water. 4-hydroxy-2,3-nonenal (HNE; Cayman Chemical, Ann Arbor, MI) was prepared as a 1000× stock in ethanol. γ -secretase inhibitors including L685,458, DAPT, compound E, WPE-III-31C, pepstatin A and β -secretase Inhibitor IV were purchased from Calbiochem (Cambridge, MA).

2.4. Immunoblots

Total cellular lysates were obtained by washing the cells in ice-cold PBS and resuspending the cell pellets in cell lysis buffer. Tissue protein was extracted using T-PER (Pierce, Rockford, IL) tissue protein extraction buffer with protease inhibitor cocktail (Sigma, St. Louis, MO). Protein concentration was determined using a BCA protein assay kit (Pierce). Fifty micrograms of protein was separated by SDS-PAGE (4–12%) and transferred to PVDF membranes. The membranes were blocked in 5% nonfat milk for 1 h at room temperature. Membranes were then probed with antibody specific for BACE1 (a generous gift from H. Cai, Bethesda, USA) [5], or the commercially available anti-BACE1 (ProSci, Poway, CA), BACE2 (Calbiochem), PS1 (Chemicon, Temecula, CA), Nicastrin (Sigma), ADMAM10 (Chemicon), TACE (Chemicon), APP (Zymed), sAPP β (COVANCE), APP-CTFs (Sigma) and β -actin (Sigma) antibodies. Membranes were then washed and incubated with secondary antibodies for 1 h at room temperature. Protein bands were visualized using a chemiluminescence detection kit (Amersham Biosciences, Buckinghamshire, UK).

2.5. Luciferase assay

The pB1P-A plasmid contains the 2.1-kb 5' UTR from –1944 to +292 bp of the human BACE1 gene upstream of the luciferase reporter gene [7]. The luciferase assay was performed according to the manufacturer's protocol (Promega, Madison, WI). Transfected cells were harvested and lysed in 200 μ L of 1x Reporter Lysis Buffer for Dual Luciferase Assay (Promega). Twenty microliters of lysate was mixed with the firefly luciferase assay reagent II and the luminescent signal was measured using a luminometer. Stop and Glo® Reagent (100 μ L) was added to the same tube. The *Renilla* (sea pansy) luciferase vector pCMV-Rluc (Promega) was cotransfected to normalize the transfection efficiency. The firefly luciferase activity was normalized according to *Renilla* luciferase activity and expressed as relative luciferase units (RLU) to reflect the promoter activity. The empty vector pGL3-basic was used as the negative control and pGL3 promoter as the positive control.

2.6. Fluorometric detection of activities of β - and γ -secretases

The activities of β - and γ -secretases present in human brain specimens were determined using fluorescent transfer peptides consisting of APP amino acid sequences containing the cleavage sites of BACE or γ -secretase (R&D systems, Minneapolis, MN). The method is based on the secretase-dependent cleavage of a secretase-specific peptide conjugated to the fluorescent reporter molecules EDANS and DABCYL, which results in the release of a fluorescent signal that was detected using a fluorescent microplate reader with excitation wavelength of 355 nm and emission at 510 nm. The level of secretase enzymatic activity is proportional to the fluorometric reaction, and the data are expressed as fold increase in fluorescence over that of background controls (reactions in the absence of tissue or cell lysate).

2.7. Quantification of mRNA using real time reverse transcription-PCR

Total RNA was isolated from primary cultured rat neurons using QIAshredder and RNeasy kits (Qiagen Inc., Hilden, Germany). The isolated RNA (2 μ g) and oligo(dT) primers were utilized to synthesize single-stranded cDNA using a reverse transcription kit (Invitrogen,

Carlsbad, CA) according to the manufacturer's instructions. The PCR was set up using SYBR Green Master Mix (Applied Biosystems, Foster City, CA) along with 1 μ l of cDNA and the gene-specific primers at a final concentration of 0.3 μ M. Thermal cycling was carried out on an Applied Biosystems GeneAmp 7700 sequence detector, and SYBR green dye intensity was analyzed using GeneAmp 7700 SDS software. The rat BACE1 and 18 S primers were designed with the Primer3 software and were as follows: BACE1 forward 5'-CATTGCCATCACTGAAT-3', reverse 5'-CAGTGCCTCAGTCTGGTTGA-3'; 18 S forward 5'-TCATCAGACCCCAGAAAAGG-3', reverse 5'-GATTCGGCAGGTGAGTTATT-3'.

2.8. siRNA experiments

SH-SY5Y cells were transfected with 1 nM of PS1, Nicastrin, or scrambled siRNAs (Santa Cruz, Santa Cruz, CA). Each siRNA is a pool of 3 target-specific 20–25 nt siRNAs designed to knock down gene expression. For transfections, Amaxa nucleofection technology was used (Amaxa, Gaithersburg, MD). Cells were resuspended in the nucleofector V solution, available as part of the Amaxa cell optimization kit, and were electroporated. Briefly, 5×10^6 cells were aliquoted in 100 μ l with 10 μ l of siRNA and were transferred to a cuvette and nucleofected with the Amaxa Nucleofector device. Cells were immediately transferred into wells containing 37°C pre-warmed culture medium in 6-well plates. All experiments were performed in triplicate. At days 1–2 after electroporation, the expression level of PS1, Nicastrin, BACE1 and β -actin were analysed by immunoblotting.

2.9. A β quantitative assay

Secreted A β 42 levels in the cell culture media were quantitatively measured using colorimetric ELISA kits (BioSource) according to the protocol provided by the manufacturer. Culture medium was collected and cleared by centrifugation ($14,000 \times g$ for 10 min at 4°C), and a 100 μ l sample of the medium was used for A β measurement.

2.10. Statistical analysis

Statistical differences were analyzed using one-way ANOVA tests. Multiple comparisons were performed using a *post-hoc* Dunnett *t*-test.

3. Results

3.1 γ -secretase activity affects BACE1 expression

Because the activities of both β -secretase and γ -secretase are required to produce A β , we first determined whether there is a relationship between β -secretase and γ -secretase activities in AD brains. We observed a positive correlation between β - and γ -secretase activities in rapidly autopsied (postmortem interval: 2.98 ± 0.89 h) samples from the inferior parietal cortex of AD and age-matched control subjects (Fig. 1A). However, there was not a significant correlation between β -secretase activity and γ -secretase activity in parietal lobe within the AD patient group or the non-dementia control group, suggesting that the correlation in the pooled sample data may be due to the fact that AD patients, on average, have higher activities of both β - and γ -secretases compared to non-dementia controls. In samples from cerebellum, a brain region with little or no amyloid pathology, we found no significant correlation between β - and γ -secretase activities in the samples from AD and age-matched control subjects (Fig. 1A). This finding prompted us to determine if γ -secretase activity affects BACE1 expression. We tested this hypothesis by determining the effect of several potent γ -secretase inhibitors on BACE1 levels in culture neurons. First, we checked BACE1 levels in wild-type and BACE1^{-/-} MEFs after treatment with HNE, a lipid peroxidation product previously implicated in the pathogenesis of AD [12,15,16].

Expression of BACE1 was increased by HNE in wild-type mouse embryonic fibroblasts (MEF), in agreement with previous results (Fig. 1B) [28]. Also, BACE1 was not detected in BACE1^{-/-} MEFs, demonstrating that anti-BACE1 antibody successfully recognized BACE1 protein. BACE1 levels were increased and primary cultured cortical neurons treated with lipid peroxidation product 4-hydroxy-2,3 nonenal (HNE) (Fig. 1B-C). The HNE-mediated BACE1 induction was suppressed by treatment with several γ -secretase inhibitors (ComE, L685, 31C and PepA), but not by a β -secretase inhibitor (BI4) (Fig. 1C). These results were confirmed in primary cultured hippocampal neurons where HNE enhanced the expression of BACE1 in a γ -secretase-dependent manner (Fig. 1D). However, levels of two putative α -secretases, ADAM10 and TACE, were not changed by γ -secretase inhibition or by exposure to HNE (Fig. 1D), supporting specific effects of HNE and γ -secretase on BACE1 levels. Indeed, the levels of the BACE1 homolog BACE2 and the catalytic component of γ -secretase presenilin-1 (PS1) were not changed by HNE and γ -secretase inhibitors (Fig. 1D).

3.2 γ -secretase inhibitors reduce β -secretase activity and the production of sAPP β

We next performed experiments to determine the effects of HNE or secretase inhibitors on the production of APP, sAPP β , A β 42, and APP C-terminal fragments (APP-CTFs) (Fig. 2). First, we determined whether the lipid peroxidation product HNE induces β -secretase, γ -secretase activities, and A β 42 production. Indeed, HNE enhanced the production of A β 42 and the activities of β -secretase and γ -secretase, and these effects of HNE were blocked by inhibitors of the respective secretases (Fig. 2A and 2B). However, γ -secretase inhibitors also suppressed β -secretase activity (Fig. 2A). Consistent with our finding that HNE-mediated BACE1 induction was suppressed by γ -secretase inhibitors (Fig. 1), the production of sAPP β was significantly reduced by γ -secretase inhibitors, whereas the levels of full-length APP and APP-CTFs were not affected by HNE (Fig. 2C). All of these results support the hypothesis that γ -secretase induces BACE1 production and activity under conditions of oxidative stress.

3.3 PS1/ γ -secretase is required for oxidative stress-mediated BACE1 induction

We next examined the oxidative stress-mediated induction of BACE1 in MEF from wild-type, PS1^{-/-}, PS2^{-/-} and PS1^{-/-}/PS2^{-/-} mice. Hydrogen peroxide and HNE induced the expression of BACE1 in the wild-type MEF, but not in PS1^{-/-} MEF (Fig. 3A). Oxidative stress-induced BACE1 expression was completely abolished in the PS1^{-/-}/PS2^{-/-} MEF (Fig. 3B), and partially reduced in the PS2^{-/-} MEF, compared to wild-type MEF (Fig. 3C). We confirmed that γ -secretase inhibition could suppress oxidative stress-mediated induction of BACE1 in the wild-type MEF (Fig. 3B). In agreement with the results obtained in PS1 null cells, we found that down-regulation of endogenous γ -secretase using siRNAs targeting PS1 and Nicastrin resulted in reduced-BACE1 expression and *BACE1* promoter activity (Fig. 3D-E). These results indicate that PS1/ γ -secretase is required for the increased production of BACE1 in response to oxidative stress.

3.4 γ -secretase activity modulates BACE1 expression at the transcriptional level

To examine whether transcription of BACE1 can be affected by γ -secretase activity, quantitative PCR was performed. Using real time PCR, we found that levels of BACE1 mRNA are increased in response to HNE, and that this effect is blocked by γ -secretase inhibition (Fig. 4A). The promoter activity of BACE1 was also increased by HNE in a γ -secretase-dependent manner (Fig. 4B). The effects of PS1 reconstitution on BACE1 expression were evaluated by transient expression of several familial AD-causing PS1 mutants (PS1-M146V and PS1- Δ E9) in the PS1^{-/-}/PS2^{-/-} MEF. We found increased *BACE1* promoter activity following transfection with wild-type PS1, PS1-M146L and PS1- Δ E9 (Fig. 4C). In the presence of HNE, wild-type PS1 and all of the FAD PS1 mutants

showed similar levels of BACE1 promoter activities (Fig. 4C). We consistently observed that the loss-of-function mutations PS1-D257A and PS1-D385A, in which the aspartate residue essential for endoproteolysis and γ -secretase activity is replaced with an alanine residue, did not affect the level of *BACE1* promoter activity (Fig. 4C).

The γ -secretase mediated cleavage of APP leads to the formation of A β and an intracellular APP domain called AICD. We therefore examined whether AICD overexpression could modulate *BACE1* in PS-deficient cells. Transfection of AICD increased the transactivation of BACE1 promoters (Fig. 4C), and led to a dose-dependent increase in BACE1 levels in the Western blot analysis (Fig. 4D). Cells expressing PS1 mutants exhibit a significant increase of the BACE1 promoter activity in the absence of HNE; however, no significant increase is observed after HNE is applied. By contrast, when we transfected AICD the addition of HNE induced a further increase in BACE1 promoter activity. These data suggest the possibility that oxidative stress and AICD production may saturate BACE1 promoter activity in cells overexpressing mutant PS1.

3.5 γ -secretase inhibitor reduces BACE1 expression in the brains of AD model mice

To determine if BACE1 expression is regulated by γ -secretase *in vivo*, we measured BACE1 levels in cerebral cortical tissue samples from PS1 mutant knock-in mice bearing the PS1 M146L mutation (PS1KI mice), from triple-transgenic AD (3xTgAD) mice (mice expressing APP, PS1 and tau mutations), and from age matched wild-type control mice. We found that the level of BACE1 was significantly higher in the cortex of PS1KI and 3xTgAD mice compared to wild-type mice (Fig. 5). The expression of BACE1 was significantly reduced by treatment with a γ -secretase inhibitor compared to vehicle-treated control littermates (Fig. 5). These results suggest that PS1 positively regulates BACE1 expression *in vivo* in a γ -secretase activity-dependent manner.

4. Discussion

Our data suggest that, by generating AICD, γ -secretase induces transcription of the *BACE1* gene resulting in increased production of BACE1, increased β -secretase cleavage of APP and increased production of A β . In addition, A β may itself increase γ -secretase activity by inducing membrane-associated oxidative stress and HNE production [15,16]. AICD mediates transcriptional up-regulation of BACE1 expression in response to membrane-associated oxidative stress, a mechanism consistent with evidence suggesting that AICD can translocate to the nucleus and regulate gene transcription [13,26].

Apart from BACE1, other genes including tetraspanin KAI1/CD82, APP, glycogen synthase kinase-3 β (GSK-3 β) and Neprilysin have been suggested to be regulated by AICD [26,2,11,22], although regulation of some of these genes is still controversial [9,6]. We showed that overexpression of AICD increases BACE1 transcription and protein levels. We also found that selective inhibition of γ -secretase blocked oxidative stress-mediated BACE1 expression, but did not affect BACE1 expression in the absence of oxidative stress. These observations suggest, not surprisingly, that BACE1 expression is likely controlled by multiple transcription factors.

In agreement with the idea that γ -secretase activity is needed for oxidative stress-mediated BACE1 induction, we found that BACE1 protein levels and *BACE1* promoter activity are decreased under basal conditions when PS1 or nicastrin levels are decreased using RNA interference methods. On the other hand, treatment of neurons with γ -secretase inhibitors has no effect on the basal BACE1 mRNA level or BACE1 promoter activity, indicating that γ -secretase activity is required for the BACE1 induction by oxidative stress while its basal expression is independent of γ -secretase activity. It has been reported that γ -secretase

activity is not directly required for several functions of PS1 including protein trafficking, Wnt-mediated signaling, PI3K/Akt and GSK-3 β signaling and calcium regulation [23]. However, the ability of γ -secretase inhibitors to block the effects of oxidative stress on BACE1 expression suggests an important role for γ -secretase activity in the amyloidogenic effect of oxidative stress.

Free radical accumulation and peroxidative membrane damage similar to that observed in AD brains has been shown to increase A β generation in cell culture and animal models and may also mediate synaptic and cognitive dysfunction [16]. Previous studies have shown BACE1 protein levels and enzyme activity are elevated in brain regions affected by AD [10,14], suggesting that abnormal BACE1 activity contributes significantly to AD pathogenesis. Our findings suggest a mechanism for the induction and amplification of A β production in AD. We found that levels of β -secretase and γ -secretase activities were greater in postmortem brain tissue from AD patients compared to control subjects. Oxidative stress and membrane lipid peroxidation, which are known to be increased during brain aging and more so in AD [16], increased β -secretase expression which was blocked in PS-deficient cells, and prevented by γ -secretase inhibitors. We also showed that γ -secretase inhibitors suppress the expression of BACE1 in the 3xTgAD mouse model of AD. Interestingly, we found that ischemia/hypoxia [1] and oxidative increased γ -secretase activity further supporting the idea that induction of BACE1 by oxidative stress is mediated by γ -secretase.

It has been well-established that oxidative damage to lipids and proteins increases in the brain during aging and more so in AD. Lipid peroxidation and the accumulation of HNE have been localized to sites of A β deposition and neuronal degeneration in the brains of AD patients [19,4]. Cell culture studies have shown that during the process of aggregation A β can induce membrane lipid peroxidation and the accumulation of HNE in neurons, and that HNE may contribute to the neurotoxic effects of A β [12]. The present findings suggest that lipid peroxidation and HNE enhance amyloidogenic processing of APP, resulting in increased production of A β . Whereas increased production of A β appears to be the factor that initiates disease in familial AD cases caused by APP or PS mutations, our findings suggest that age-related increases in oxidative stress may be responsible, at least in part, for the increased production of A β in sporadic late-onset AD. The available data therefore suggest the involvement of a feed-forward pathogenic mechanism of AD in which lipid peroxidation increases A β production which, in turn, enhances lipid peroxidation.

Acknowledgments

This research was supported by the Intramural Research Program of the National Institute on Aging, NIH, and by a Korea Research Foundation Grant to D.G.J. (MOEHRD, Basic Research Promotion Fund) (KRF-2007-313-C00526).

5. References

1. Arumugam TV, Chan SL, Jo DG, Yilmaz G, Tang SC, Cheng A, Gleichmann M, Okun E, Dixit VD, Chigurupati S, Mughal MR, Ouyang X, Miele L, Magnus T, Poosala S, Granger DN, Mattson MP. Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. *Nat. Med* 2006;12:621–623. [PubMed: 16680150]
2. Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, Rosenfeld MG. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. *Cell* 2002;110:55–67. [PubMed: 12150997]
3. Barja G. Free radicals and aging. *Trends Neurosci* 2004;27:595–600. [PubMed: 15374670]
4. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. *Neurobiol. Aging* 2002;23:655–664. [PubMed: 12392766]

5. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major beta-secretase for generation of A β peptides by neurons. *Nat. Neurosci* 2001;4:233–234. [PubMed: 11224536]
6. Chen AC, Selkoe DJ. Presenilin-Dependent Transcriptional Control of the A β -Degrading Enzyme Neprilysin by Intracellular Domains of betaAPP and APLP. *Neuron* 2007;53:479–483. [PubMed: 17296549]
7. Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S, Song W. Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase. *Sp1. Mol. Cell Biol* 2004;24:865–874.
8. Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. *Nat. Med* 1996;5:101–106. [PubMed: 9883847]
9. Hebert SS, Serneels L, Tolia A, Craessaerts K, Derks C, Filippov MA, Müller U, De Strooper B. Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes. *EMBO Rep* 2006;7:739–745. [PubMed: 16729020]
10. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression of the amyloid precursor β -secretase in Alzheimer's disease. *Ann. Neurol* 2002;51:783–786. [PubMed: 12112088]
11. Kim HS, Kim EM, Lee JP, Park CH, Kim S, Seo JH, Chang KA, Yu E, Jeong SJ, Chong YH, Suh YH. C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3 β expression. *FASEB J* 2003;17:1951–1953. [PubMed: 12923068]
12. Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Waeg G, Mattson MP. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. *J. Neurochem* 1997;69:273–284. [PubMed: 9202320]
13. Kimberly WT, Zheng JB, Guenetta SY, Selkoe DJ. The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. *J. Biol. Chem* 2001;276:40288–40292. [PubMed: 11544248]
14. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y. Amyloid β peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. *Proc. Natl. Acad. Sci. USA* 2004;101:3632–3637. [PubMed: 14978286]
15. Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. *J. Neurosci* 1997;17:1046–1054. [PubMed: 8994059]
16. Mattson MP. Pathways towards and away from Alzheimer's disease. *Nature* 2004;430:631–639. [PubMed: 15295589]
17. Mattson MP, Barger SW, Begley JG, Mark RJ. Calcium, free radicals, and excitotoxic neuronal death in primary cell culture. *Methods Cell Biol* 1995;46:187–216. [PubMed: 7541884]
18. Montine KS, Olson SJ, Amarnath V, Whetsell WO Jr, Graham DG, Montine TJ. Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of *APOE4*. *Am. J. Pathol* 1997;150:437–443. [PubMed: 9033259]
19. Montine KS, Reich E, Neely MD, Sidell KR, Olson SJ, Markesbery WR, Montine TJ. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype. *J. Neuropathol. Exp. Neurol* 1998;57:415–425. [PubMed: 9596412]
20. National Institute on Aging and Reagan Institute Working Group. Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. *Neurobiol. Aging* 1997;18:S1–S2. [PubMed: 9330978]
21. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kaye R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A β and synaptic dysfunction. *Neuron* 2003;39:409–421. [PubMed: 12895417]
22. Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves da Costa C, Vincent B, Ring S, D'Adamio L, Shen J, Müller U, St George Hyslop P, Checler F. Presenilin-dependent transcriptional control of the A β -degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. *Neuron* 2005;46:541–554. [PubMed: 15944124]

23. Parks A,L, Curtis D. Presenilin diversifies its portfolio. *Trends Genet* 2007;23:140–150. [PubMed: 17280736]
24. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. *Ann. Neurol* 2000;48:809–812. [PubMed: 11079549]
25. Pratico D, Uryu K, Leight S, Trojanowski JQ, Lee VM. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. *J. Neurosci* 2001;21:4183–4187. [PubMed: 11404403]
26. von Rotz RC, Kohli BM, Bosset J, Meier M, Suzuki T, Nitsch RM, Konietzko U. The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. *J. Cell. Sci* 2004;117:4435–4448. [PubMed: 15331662]
27. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, Staufenbiel M, Huang LE, Song W. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. *Proc. Natl. Acad. Sci. USA* 2006;103:18727–18732. [PubMed: 17121991]
28. Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, Pronzato MA, Danni O, Smith MA, Perry G, Tabaton M. Oxidative stress increases expression and activity of BACE in NT₂ neurons. *Neurobiol. Dis* 2002;10:279–288. [PubMed: 12270690]
29. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, Muraca G, Danni O, Zhu X, Smith MA, Perry G, Jo DG, Mattson MP, Tabaton M. Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. *J. Neurochem* 2008;104:683–695. [PubMed: 18005001]
30. Wen Y, Onyewuchi O, Yang S, Liu R, Simpkins JW. Increased beta-secretase activity and expression in rats following transient cerebral ischemia. *Brain Res* 2004;1009:1–8. [PubMed: 15120577]
31. Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, Logan S, Maus E, Citron M, Berry R, Binder L, Vassar R. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. *J. Neurosci* 2007;27:3639–3649. [PubMed: 17409228]

Figure 1.

Evidence that γ -secretase induces an increase in β -secretase levels in AD. (A) Linear regression analysis of β -secretase and γ -secretase activities in inferior parietal lobule and cerebellum from clinically diagnosed and neuropathologically confirmed AD (open rectangle; $\square$) and non-demented control subjects (filled rectangle; $\blacksquare$). (B) Wild-type and BACE^{-/-} MEFs were exposed to HNE (15 μ M) for 2 hours. BACE1 levels were examined by immunoblot analysis. (C, D) Effects of γ -secretase inhibitors (GSI) on HNE-mediated induction of BACE1. Primary cultured rat cortical (C) and hippocampal (D) neurons were pretreated with the indicated inhibitors (compound E, 10 nM; L685,458, 2 μ M; WPE-III-31C, 2 μ M; pepstatin A, 2 μ M; β -secretase Inhibitor IV, 2 μ M) for 2 hours, and then cells were exposed to HNE for 16 hours. BACE1, BACE2, PS1, ADAM10, TACE, and β -actin levels were evaluated by immunoblot analysis.

Figure 2.

Oxidative stress-mediated β -secretase activity and sAPP β levels are reduced by γ -secretase inhibitors. (A) The lipid peroxidation product HNE enhances β - and γ -secretase activities. SH-SY5Y cells were pre-incubated with the β -secretase inhibitor BI4 or the γ -secretase inhibitors DAPT and L685,458 for 1 h before treatment with HNE. Cells were collected after 24 h of incubation with 5 μ M or 10 μ M HNE. The cell lysates were tested for β - and γ -secretase activities by addition of secretase-specific peptide substrate conjugated to the reporter molecules EDANS and DABCYL. (B) HNE treatment increased the amounts of secreted A β 42. After treatment of SH-SY5Y cells stably expressing mutant (Swedish) APP for 24 h, medium was harvested and analyzed by a sandwich ELISA for specific quantification of secreted A β 42. (C) γ -secretase inhibitors suppress HNE-induced sAPP β levels. After treatment of SH-SY5Y cells stably expressing wild type APP for 24 h, cells were harvested and analyzed by Western blots for APP, APP-CTFs and actin. Culture media were also analyzed by Western blot for sAPP β .

Figure 3.

Oxidative stress-induced BACE1 expression is reduced in presenilin-deficient cells. (A, B) Wild type, PS1^{-/-} (A) and PS1^{-/-}/PS2^{-/-} (PS^{-/-}) MEFs (B) were treated with HNE (5, 10, and 15 μM) or H₂O₂ (10, 20, and 50 μM) for 3 hours. Some wild-type cells were also co-treated with GSI (2 μM L685,458). BACE1, BACE2, PS1, and β-actin protein levels were measured by immunoblot analysis. (C) Oxidative stress-induced BACE1 expression is partially reduced in PS2 deficient cells. Wild type, PS1^{-/-} and PS1^{-/-}/PS2^{-/-} MEFs were treated with HNE (5, 10, and 15 μM) or H₂O₂ (10, 20, and 50 μM) for 3 hours. BACE1, BACE2, PS1, and β-actin expression were evaluated by immunoblot analysis. (D, E) SH-SY5Y cells were transfected with BACE1 promoter construct pBIP-A, in combination with PS1 or Nicastrin siRNAs. At 36 hours, cells were harvested and analyzed for BACE1 promoter activity by dual-luciferase assay (D) or were used to examine levels of PS1, Nicastrin, BACE1, and β-actin by immunoblotting (E). Values are the mean and SD of three independent experiments. **P* < 0.01 compared to control.

Figure 4.

γ -secretase proteins regulate BACE1 promoter activity. (A) Quantitative real time PCR analysis was performed on RNA samples from rat cortical neurons that had been exposed for 3 hours to the indicated treatments. γ -secretase inhibitors (compound E, 10 nM; L685,458, 2 μ M) were added for 2 hours before HNE exposure. Values are the means and SD of 3 independent experiments. (B) HNE increases human BACE1 promoter activity, an effect suppressed by γ -secretase inhibitors. SH-SY5Y cells were transfected with BACE1 promoter constructs pB1P-A or pGL3-Basic (negative control) in association with renilla luciferase vector pCMT-Rluc to verify transfection efficiency. Twenty four hours after transfection, cells were treated for 3 hours with HNE in the presence of the indicated γ -secretase inhibitors (compound E, 10 nM; L685,458, 2 μ M). BACE1 transcriptional activity was measured using a dual-luciferase assay. Values are the mean and SD of three independent experiments. * P < 0.01 compared to control, # P < 0.01 and ## P < 0.001 compared to the 10 μ M HNE treated samples. (C) BACE1 promoter activity is increased by PS1, FAD PS1 mutations and AICD in PS-deficient cells. PS^{-/-} fibroblasts were transiently co-transfected with pB1P-A and PS1, PS1-M146L, PS1-ΔE9, PS1-D257A, PS1-D385A, or AICD. After 24 hr incubation, BACE1 promoter activity was analyzed. Results were obtained from four independent experiments, each performed in triplicate (mean and SD). * P < 0.01 compared to vector transfected control. (D) BACE1 protein levels are increased by AICD expression. PS^{-/-} fibroblasts were transiently transfected with increasing amounts of AICD cDNA, and then BACE1 and β -actin levels were measured by immunoblot analysis.

Figure 5.

γ -secretase inhibitor reduces BACE1 expression in the brains of AD model mice. PS1KI and 3xTgAD mice were injected with γ -secretase inhibitor (GSI) or vehicle every day for 7 days. (A) Cerebral cortex tissue was homogenized and BACE1 and β -actin levels were examined by immunoblots. (B) Quantitative analysis showed increased levels of BACE1 in PS1KI and 3xTgAD mice compared to wild type mice, and a significant reduction following γ -secretase inhibitor treatment. Values are the means and SD (5 mice/group). * $P < 0.001$ and ** $P < 0.05$ compared to wild-type. # $P < 0.01$.